Cargando…

The feasibility of quantitative MRI of extra‐ocular muscles in myasthenia gravis and Graves' orbitopathy

Although quantitative MRI can be instrumental in the diagnosis and assessment of disease progression in orbital diseases involving the extra‐ocular muscles (EOM), acquisition can be challenging as EOM are small and prone to eye‐motion artefacts. We explored the feasibility of assessing fat fractions...

Descripción completa

Detalles Bibliográficos
Autores principales:	Keene, Kevin R., van Vught, Luc, van de Velde, Nienke M., Ciggaar, Isabeau A., Notting, Irene C., Genders, Stijn W., Verschuuren, Jan J.G.M., Tannemaat, Martijn R., Kan, Hermien E., Beenakker, Jan‐Willem M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757175/ https://www.ncbi.nlm.nih.gov/pubmed/32893386 http://dx.doi.org/10.1002/nbm.4407

Ejemplares similares

Eye Muscle MRI in Myasthenia Gravis and Other Neuromuscular Disorders
por: Keene, Kevin R., et al.
Publicado: (2023)

Myasthenia Gravis Impairment Index: Sensitivity for Change in Generalized Muscle Weakness
por: de Meel, Robert H.P., et al.
Publicado: (2020)

Ocular Weakness in Myasthenia Gravis: Changes in Affected Muscles are a Distinct Clinical Feature
por: de Meel, Robert H.P., et al.
Publicado: (2019)

Clinical and imaging clues to the diagnosis and follow‐up of ptosis and ophthalmoparesis
por: Keene, Kevin R., et al.
Publicado: (2022)

Treating muscle-specific kinase myasthenia gravis from the inside out
por: Huijbers, Maartje G., et al.
Publicado: (2019)

Sensitivity of MG‐ADL for generalized weakness in myasthenia gravis
por: de Meel, R. H. P., et al.
Publicado: (2018)

Assessing facial weakness in myasthenia gravis with facial recognition software and deep learning
por: Ruiter, Annabel M., et al.
Publicado: (2023)

Upper eyelid retraction disclosed after edrophonium chloride administration in a patient with Graves’ orbitopathy and myasthenia gravis
por: Kang, Hyera, et al.
Publicado: (2012)

Graves' Orbitopathy
por: Hiromatsu, Yuji, et al.
Publicado: (2015)

Asymmetric Graves’ Orbitopathy
por: Panagiotou, Grigorios, et al.
Publicado: (2020)

Rare Co-occurrence of Ocular Myasthenia Gravis and Thyroid-Associated Orbitopathy (Ophthalmopathy) in an Individual With Hypothyroidism
por: An, Ran, et al.
Publicado: (2019)

Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy
por: Lanzolla, G., et al.
Publicado: (2022)

Graves’ disease and Graves’ orbitopathy following COVID-19
por: Lanzolla, G., et al.
Publicado: (2021)

Planning health care for patients with Graves’ orbitopathy
por: Sasim, Inna V., et al.
Publicado: (2008)

The Role of the Microbiota in Graves’ Disease and Graves’ Orbitopathy
por: Hou, Jueyu, et al.
Publicado: (2021)

Graves′ orbitopathy: Management of difficult cases
por: Wiersinga, Wilmar M.
Publicado: (2012)

Antioxidant Therapy in Graves’ Orbitopathy
por: Lanzolla, Giulia, et al.
Publicado: (2020)

Current Knowledge on Graves’ Orbitopathy
por: Gontarz-Nowak, Katarzyna, et al.
Publicado: (2020)

Orbital Signaling in Graves’ Orbitopathy
por: Draman, Mohd Shazli, et al.
Publicado: (2021)

Selection Approach to Identify the Optimal Biomarker Using Quantitative Muscle MRI and Functional Assessments in Becker Muscular Dystrophy
por: van de Velde, Nienke M., et al.
Publicado: (2021)

Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement
por: Perros, P., et al.
Publicado: (2017)

Myasthenia gravis
por: Juel, Vern C, et al.
Publicado: (2007)

Glucocorticoids in Graves’ orbitopathy: mechanisms of action and clinical application
por: Längericht, Jan, et al.
Publicado: (2020)

MuSK myasthenia gravis monoclonal antibodies: Valency dictates pathogenicity
por: Huijbers, Maartje G., et al.
Publicado: (2019)

Adipocytokines in Graves’ orbitopathy and the effect of high-dose corticosteroids
por: Schovanek, Jan, et al.
Publicado: (2021)

Surgical complications in orbital decompression for Graves' orbitopathy
por: Sellari-Franceschini, S., et al.
Publicado: (2016)

Endoscopic orbital decompression for Graves’ orbitopathy
por: Lal, Priti, et al.
Publicado: (2013)

Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2020)

Current concepts regarding Graves’ orbitopathy
por: Bartalena, Luigi, et al.
Publicado: (2022)

Update on the surgical management of Graves’ orbitopathy
por: Baeg, Joonyoung, et al.
Publicado: (2023)

Significance of HLA in the development of Graves’ orbitopathy
por: Stasiak, Magdalena, et al.
Publicado: (2023)

Serum thyroglobulin is associated with orbitopathy in Graves’ disease
por: Khamisi, S., et al.
Publicado: (2021)

Thymectomy in Myasthenia Gravis
por: Dunlop, D. M.
Publicado: (1953)

Stimulatory Thyrotropin Receptor Antibodies Are a Biomarker for Graves’ Orbitopathy
por: George, Augustine, et al.
Publicado: (2021)

Myasthenia Gravis
por: Aarli, Johan A., et al.
Publicado: (2011)

Myasthenia Gravis
Publicado: (1905)

Myasthenia Gravis
por: Wilson, Andrew
Publicado: (1952)

Myasthenia Gravis
por: Bramwell, Edwin
Publicado: (1901)

Thymectomy for myasthenia gravis
por: Moorehead, R J, et al.
Publicado: (1985)

Sirolimus as a second-line treatment for Graves’ orbitopathy
por: Lanzolla, G., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_59kjgfi11v0cl370thcnn6cg17